AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. While there is significant liquidity and completion of capital expenditures, revenue trends are declining, and R&D expenses have increased. The Q&A reveals potential in ABCL575 and ABCL635 but lacks specifics on timelines and patient numbers. Revenue increase from patent settlements is positive, but the net loss remains significant. The absence of guidance adjustments and unclear management responses contribute to a neutral sentiment.
Key Financial Performance
Revenue Revenue for the year was $75 million, comprising $27 million relating to work on partnered programs and $47 million from licensing and royalty payments. This compares to a total revenue of approximately $29 million in 2024. $36 million of the licensing and royalty stems from settling our patent infringement claims against Bruker.
Research and Development Expenses Research and development expenses for the year were $187 million, approximately $20 million more than last year. This expense reflects the focus on investment in our internal programs.
Sales, General and Administration Expenses Sales, general and administration expenses were approximately $83 million compared to roughly $86 million in 2024. Included in these expenses in both years are costs related to the now settled Bruker litigation.
Net Loss Net loss of roughly $146 million for the year compared to a loss of about $163 million last year. In terms of earnings per share, this result works out to a loss of $0.49 per share on a basic and diluted basis.
Operating Cash Usage Operating activities for all of 2025 used approximately $130 million in cash and equivalents. Excluding liquidity received from marketable securities and real estate, all other investment activities amounted to $46 million for the year.
Liquidity Finished the quarter with $561 million of total cash, cash equivalents and marketable securities. With over $560 million in cash and equivalents and the unused portion of our secured government funding, we have approximately $700 million in available liquidity to execute on our strategy.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pipeline Expansion: In 2025, AbCellera's pipeline grew from 2 preclinical programs to 4 programs, including ABCL688 (autoimmunity) and ABCL386 (oncology). Both are in IND-enabling activities, with Phase I/II studies planned for 2027. Over 20 additional programs are in discovery, with a fifth program expected to enter IND-enabling activities in early 2026.
Clinical Trials: ABCL635 advanced to a Phase II study, with results expected in Q3 2026. ABCL575 is in Phase I. Positive results for ABCL635 could lead to late-stage development for menopause-related hot flashes and cancer treatment-related hot flashes.
Market Potential: ABCL635 has blockbuster potential if Phase II results meet target product profiles, including efficacy comparable to Lynkuet and VEOZAH, a differentiated safety profile, and dosing convenience.
Manufacturing Facility: AbCellera completed its clinical manufacturing facility, enhancing supply chain control, flexibility, timelines, and IP protection.
Financial Position: Ended 2025 with $700 million in liquidity, including $560 million in cash and equivalents and $140 million in government funding. Revenue for 2025 was $75 million, up from $29 million in 2024. Net loss reduced to $146 million from $163 million in 2024.
Shift to Clinical Stage Biotech: Transitioned from platform building to pipeline development, focusing on first-in-class opportunities and advancing clinical programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Scientific risk in achieving sufficient target engagement: The company identified a key scientific risk in achieving sufficient target engagement of KNDy neurons in the infundibular nucleus for their lead program ABCL635. This could impact the efficacy of the drug and its progression to late-stage development.
Incomplete understanding of hot flash biology: The company acknowledges that their understanding of the biology of hot flashes is incomplete, which introduces uncertainty in the success of their lead program ABCL635.
Dependency on positive Phase II readout: The progression of ABCL635 to late-stage clinical development and the company's transition to a late-stage clinical company is heavily dependent on a positive Phase II readout. A negative outcome could delay strategic objectives.
High R&D expenses: The company reported $187 million in R&D expenses for 2025, reflecting a significant investment in internal programs. This high expenditure could strain financial resources if expected outcomes are not achieved.
Revenue decline from research fees: The company expects research fee revenues to trend lower as they focus on internal pipeline development, which could impact short-term revenue generation.
Attrition in partner-initiated programs: Approximately half of all partner-initiated programs with downstream participation are no longer progressing, which could impact future revenue from milestones and royalties.
Reliance on government funding: The company relies on $140 million in committed government funding to execute its strategy. Any changes in government support could impact their financial stability.
Supply chain and manufacturing risks: While the company has invested in a clinical manufacturing facility to control supply chain and protect intellectual property, any operational issues or delays in this facility could impact timelines and costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Development: AbCellera plans to submit INDs or CTAs for ABCL688 and ABCL386 and initiate Phase I/II studies in 2027. They also anticipate advancing a fifth program into IND-enabling activities in the first half of 2026. By mid-2027, they expect to have 5 clinical stage programs across various indications in large markets.
Clinical Readouts: The most critical data disclosure in 2026 will be the Phase II readout of ABCL635, anticipated in Q3. A positive outcome could lead to late-stage development for hot flashes associated with menopause and potentially cancer treatment. ABCL575 Phase I study results are also expected in 2026.
Capital and Liquidity: With approximately $700 million in available liquidity, AbCellera believes it has sufficient capital to fund its pipeline investments and strategic initiatives for the next three years.
Strategic Focus: The company is shifting its focus from platform building to pipeline development, emphasizing first-in-class opportunities and advancing its proprietary programs.
Market Potential: ABCL635 has blockbuster potential if it demonstrates efficacy comparable to existing treatments like Lynkuet and VEOZAH, with a differentiated safety profile and dosing convenience.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company thinking about the potential for ABCL575 as a combination regimen?
A:The company sees OX40 ligand as a class with a broad effect on the immune system, good durability, and an attractive safety profile for combinations. They are exploring both internal and external opportunities for combination regimens. ABCL575 is currently in a Phase I trial, with results expected by the end of the year.
Q:What oncology-based VMS studies are being considered, and how does the company view competition with other agents like elinzanetant?
A:The company is exploring breast cancer (patients on aromatase inhibitors, tamoxifen, or post-oophorectomy) and prostate cancer (men on ADT or AR pathway inhibitors). They believe even equivalent efficacy offers differentiation through safety (no liver signal, no liver monitoring) and convenience (once-monthly dosing). Improved efficacy is seen as a potential upside.
Q:Can you expand on the encouraging target engagement data for 635 and its implications for VMS?
A:The Phase I study data, including safety and target engagement, will be released alongside Phase II data in Q3. The company remains confident in the OX40 ligand class despite safety concerns like Kaposi sarcoma, which they view as not unexpected and consistent with other immunomodulatory drugs. They believe the class has strong potential both as monotherapy and in combination.
Q:What will the Q3 update for 635 include in terms of patient numbers, doses, and follow-up?
A:The Q3 update will include Phase I single and multiple ascending dose portions (3 doses spread 4 weeks apart) and the randomized, double-blind, placebo-controlled Phase II study. The key readout will focus on 4-week efficacy (frequency and severity of hot flashes) and safety, with preliminary quality of life measures.
Q:How much clinical trial infrastructure can the company maintain, and how many programs can they actively develop?
A:The company has reshaped its internal resources to focus on biology, translational medicine, early development, and clinical development. They are building operational capacity to handle multiple programs, including a potential Phase III study for 635 and a new development candidate in the first half of the year.
Q:What factors will influence the decision to further develop or out-license 575 by 2027?
A:The decision will largely depend on external factors, such as partnerability and strategic appetite. Internally, the molecule has met expectations in Phase I with no surprises. The company is also considering its use in combination or as a bispecific.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the Q3 update for 635, such as exact patient numbers and dose ranges, and used general language about the company's operational capacity without concrete examples or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABCL IND
ABCL Phase
Booth Chief
CEO Booth
CTAs program
Chelsea portion
Chief Legal
II ABCL
II portion
II readout
II study
IND activity
INDs CTAs
Legal Compliance
Officer projection
Officer today
Phase II
Phase portion
Phase program
Today program
VEOZAH safety
activity INDs
activity development
activity disclosure
addition Phase
advantage convenience
antibody drug
candidate liquidity
discovery
drug candidate
initiation
neuron
portion study
program ABCL
readout potential
scenario
study flash
success
today Chief
ABCL Transcript
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call presents mixed signals. While there is significant liquidity and completion of capital expenditures, revenue trends are declining, and R&D expenses have increased. The Q&A reveals potential in ABCL575 and ABCL635 but lacks specifics on timelines and patient numbers. Revenue increase from patent settlements is positive, but the net loss remains significant. The absence of guidance adjustments and unclear management responses contribute to a neutral sentiment.
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-8
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-22
ABCL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
